Loading...
OTCM
GRTSQ
Market cap0kUSD
Apr 03, Last price  
0.00USD
Name

Gritstone bio Inc

Chart & Performance

D1W1MN
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
66.91%
Rev. gr., 5y
2.32%
Revenues
1m
-85.64%
001,187,0004,365,0004,037,00046,717,0009,269,0001,331,000
Net income
-138m
L+22.42%
-18,750,000-41,377,000-64,775,000-90,926,000-104,611,000-74,955,000-113,127,000-138,490,000
CFO
-122m
L+4.92%
-15,292,000-34,971,000-38,162,000-85,011,000-89,102,000-50,678,000-115,946,000-121,648,000
Earnings
Aug 11, 2025

Profile

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
IPO date
Sep 28, 2018
Employees
233
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
1,331
-85.64%
9,269
-80.16%
Cost of revenue
155,965
156,064
Unusual Expense (Income)
NOPBT
(154,634)
(146,795)
NOPBT Margin
Operating Taxes
7,423
(6,560)
Tax Rate
NOPAT
(162,057)
(140,235)
Net income
(138,490)
22.42%
(113,127)
50.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,092
63,847
BB yield
-3.43%
-20.35%
Debt
Debt current
13,808
5,294
Long-term debt
155,598
55,989
Deferred revenue
Other long-term liabilities
709
150
Net debt
82,543
(114,635)
Cash flow
Cash from operating activities
(121,648)
(115,946)
CAPEX
(4,572)
(5,872)
Cash from investing activities
102,341
(12,964)
Cash from financing activities
25,117
83,098
FCF
(207,361)
(134,509)
Balance
Cash
81,573
171,887
Long term investments
5,290
4,031
Excess cash
86,796
175,455
Stockholders' equity
(659,536)
(521,129)
Invested Capital
823,774
732,376
ROIC
ROCE
EV
Common stock shares outstanding
115,528
90,918
Price
2.04
-40.87%
3.45
-73.17%
Market cap
235,676
-24.86%
313,668
-69.08%
EV
318,219
199,033
EBITDA
(147,043)
(140,235)
EV/EBITDA
Interest
4,036
1,235
Interest/NOPBT